Galectin Therapeutics Inc. (GALT) P/E Ratio History
Historical price-to-earnings valuation from 2006 to 2007
Loading P/E history...
GALT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Galectin Therapeutics Inc. (GALT) trades at a price-to-earnings ratio of -2.8x, with a stock price of $2.11 and trailing twelve-month earnings per share of $-0.58.
The current P/E is 116% below its 5-year average of 17.3x. Over the past five years, GALT's P/E has ranged from a low of 1.9x to a high of 45.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, GALT trades at a 112% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, GALT trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GALT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GALT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.5Lowest | 1.11Best | -25% | |
| $7B | 50.3 | - | -4%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
GALT Historical P/E Data (2006–2007)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2007 Q2 | Sat Jun 30 2007 00:00:00 GM | $2.10 | $1.09 | 1.9x | -89% |
| FY2007 Q1 | Sat Mar 31 2007 00:00:00 GM | $4.44 | $0.90 | 4.9x | -71% |
| FY2006 Q4 | Sun Dec 31 2006 00:00:00 GM | $2.70 | $0.06 | 45.0x | +160% |
Average P/E for displayed period: 17.3x
See GALT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GALT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GALT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGALT — Frequently Asked Questions
Quick answers to the most common questions about buying GALT stock.
Is GALT stock overvalued or undervalued?
GALT trades at -2.8x P/E, below its 5-year average of 17.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does GALT's valuation compare to peers?
Galectin Therapeutics Inc. P/E of -2.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is GALT's PEG ratio?
GALT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2006-2007.